Company / Operating Income
Amgen Operating Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Income
$9.1B
FY2025
5-year range
$7.3B / $9.6B
FY2021-FY2025
Trend
+25.1%
vs FY2024
Sector context
#3 of 202
Health Care
What the data says
Among 202 Health Care companies, Amgen is in the top 1% for operating income. Operating Income returned to growth in FY2025 after 2 years of decline, reaching $9.1B.
Based on SEC 10-K filings.
$9.1B in FY2025 with a 5-year CAGR of -0.1%. Ranks 3rd among 202 companies in Health Care.
Improved from $7.9B to $9.1B over the past 2 years.
Health Care sector context is included.
Operating Income over time
Growth rates
- 3-Year CAGR
- -1.7%
- 5-Year CAGR
- -0.1%
- 10-Year CAGR
- -
Sector benchmark
Top 1% in Health CareTop 1% of 202This company $9.1B Sector average $86.7M
▼
+10376.0% above sector average
Key checks
Key Insights
- 5-year CAGR of -0.1%, indicating a declining trend.
- In FY2025, operating income increased 25.1% year-over-year.
- Ranks #3 out of 202 companies in the Health Care sector.
- Peak operating income was recorded in FY2018.
Company context
Key Data Points
- Altman Z-Score 0.55 (distress zone, below 1.8 threshold)
- Strong return on equity: 72.8%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $9.1B | +25.1% |
| FY2024 | $7.3B | -8.1% |
| FY2023 | $7.9B | -17.4% |
| FY2022 | $9.6B | +25.2% |
| FY2021 | $7.6B | -16.4% |
| FY2020 | $9.1B | -5.5% |
| FY2019 | $9.7B | -5.7% |
| FY2018 | $10.3B | +2.9% |
| FY2017 | $10.0B | +1.8% |
| FY2016 | $9.8B | +15.6% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026